

Att. Docket No.: REG 710-A-US

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN:

10/009,852

Applicant:

Papadopoulos, et al.

Date Filed:

December 6, 2001

Title: MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC

PROPERTIES AND METHODS OF MAKING AND USING THEREOF

Examiner:

Unknown

Group Art Unit:

1614

January 16, 2003

U.S. PATENT DOCUMENTS

Examiner <u>Initials</u>	Patent <u>Number</u>	Issue <u>Date</u>	Publication <u>Number</u>	Publication <u>Date</u>	<u>Name</u>
RKY	6,011,003	01/04/00			Charnock-Jones, et al.
RKH	5,712,380	01/27/98			Kendall, et al

FOREIGN PATENT DOCUMENTS

Examiner <u>Initials</u>	Document <u>Number</u>	<u>Date</u>	Country	Class/ Date Subclass	Trans <u>Yes</u>	slation <u>No</u>	
RKM	WO98/13071 ·	04/02/98	PCT				
RKH	WO97/44453	11/27/97	PCT				
RKH	WO99/03996	01/28/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Terman, B. I., et al, "Identification of a new endothelial cell growth factor receptor tyrosine kinase", Oncogene (1991) 6:1677-1683

Terman, B.I., et al, "Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor", Biochem Biophys Res Comm (1992) 187(3):1579-1586

Tsutsumi, Y., et al, "PEGylation of interleukin-6 effectively increases its thrombopoietic potency", Thrombosis and Haemostasis (1997) 77(1):168-173

	•		
Dunca, R. and 27(4):290-306		onjugates", Drug Delivery Systems (19	994)
Hileman, R.E.	., et al., "Glycosaminoglycan es in glycosaminoglycan bin	n-protein interactions: definitions of nding proteins", BioEssays (1998) 20:1	56-167
	ie, et al., "The <i>fins-</i> like tyrosi owth factor", Science (1992	ine kinase, a receptor for vascular 2) 225:989-991	
	.l., "Improving monoclonal a , Quart J Nucl Med (1998)	antibody pharmacokinetics via chemi 42:242-249	cal
Jensen-Pippo, stimulating fac 107	, K.E., et al., "Enteral bioavai ctor conjugated with poly(e	ilability of human granulocyte colony ethylene glycol)", (1996) Pharm Res 1	; 3(1):102-
		ne extracellular domain in vascular 1 Tyrosine kinase)", (1997) Jpn J Canc	er Res
Yang, J.C., et the treatment Cancer 76(4):	of patients with metastatic	e glycol-modified interleukin-2 (PEG- renal cell carcinoma and melanoma"	IL-2) in , (1995)
EXAMINER CONSIDERED	DATE		
Tarul & Hjmuth	- 1/19/04		
EXAMINER:	with MPEP 609; draw line	d, whether or not citation is in confor through citation if not in conformand opy of this form with next communica 	ce and
	Respectfully	y submitted,	
	Regeneron l	alladino nt for Applicants Pharmaceuticals, Inc. w Mill River Road	

ว

Tarrytown, New York 10591 (914) 345-7400



Att. Docket No.: REG 710-A-US

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN:

10/009,853

Applicant:

Papadopoulos, et al.

Date Filed:

December 6, 2001

Title:

e: MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC

PROPERTIES AND METHODS OF MAKING AND USING THEREOF

Examiner:

Unknown

Group Art Unit:

1614

January 28, 2003

U.S. PATENT DOCUMENTS

Examiner Initials

Patent Number Issue Date **Publication**

Publication · Name

Number

<u>Date</u>

FOREIGN PATENT DOCUMENTS

Examiner Initials

Document Number

Date

Country

Class/ Tran
Date Subclass Yes

Translation

Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

1

Davis-Smyth, T., et al., 1996, "The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction-cascade", The EMBO_Journal_15(18):4919-4927.

EXAMINER CONSIDERED

DATE

CONSIDERED

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and